Essential Therapeutics (ETRX) formerly Microcide (MCDE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (197)	5/21/1999 7:40:00 AM
From: Anaxagoras	Read Replies (1) of 415

<<How long has Hogan been there? >> According to the proxy, about 3 years. It's never good news to have a CFO leave (unless it was a mistake to acquire him in the first place), but sometimes it's neutral. Hogan's a young guy, 38, so it may simply be time to leave the purgatory of a microcap biotech (sub $50 market cap) and ascend to bigger things. Would make sense as a career move. Here's his corporate bio: <<Matthew J. Hogan, Chief Financial Officer, joined the Company in May 1996. Prior to joining the Company, he held various positions since 1986 in the investment banking group at Merrill Lynch & Co., most recently as a Director focusing on the biotechnology/pharmaceutical sector. Mr. Hogan holds a B.A. in Economics from Dartmouth College and a M.B.A. from the Amos Tuck School of Business Administration. >> Anaxagoras

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next